دورية أكاديمية
أعرض في EDS

Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.

التفاصيل البيبلوغرافية
العنوان: Treatment effect heterogeneity following type 2 diabetes treatment with GLP1-receptor agonists and SGLT2-inhibitors: a systematic review.
المؤلفون: Young KG; Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital, Exeter, UK., McInnes EH; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK., Massey RJ; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK., Kahkoska AR; Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Pilla SJ; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Raghavan S; Section of Academic Primary Care, US Department of Veterans Affairs Eastern Colorado Health Care System, Aurora, CO, USA., Stanislawski MA; Department of Biomedical Informatics, School of Medicine, University of Colorado, Aurora, USA., Tobias DK; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., McGovern AP; Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital, Exeter, UK., Dawed AY; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK., Jones AG; Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital, Exeter, UK., Pearson ER; Division of Population Health & Genomics, School of Medicine, University of Dundee, Dundee, UK. e.z.pearson@dundee.ac.uk., Dennis JM; Exeter Centre of Excellence in Diabetes (EXCEED), University of Exeter Medical School, RILD Building, Royal Devon & Exeter Hospital, Exeter, UK. j.dennis@exeter.ac.uk.
مؤلفون مشاركون: ADA/EASD PDMI
المصدر: Communications medicine [Commun Med (Lond)] 2023 Oct 05; Vol. 3 (1), pp. 131. Date of Electronic Publication: 2023 Oct 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Portfolio Country of Publication: England NLM ID: 9918250414506676 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-664X (Electronic) Linking ISSN: 2730664X NLM ISO Abbreviation: Commun Med (Lond) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Portfolio, [2021]-
مستخلص: Background: A precision medicine approach in type 2 diabetes requires the identification of clinical and biological features that are reproducibly associated with differences in clinical outcomes with specific anti-hyperglycaemic therapies. Robust evidence of such treatment effect heterogeneity could support more individualized clinical decisions on optimal type 2 diabetes therapy.
Methods: We performed a pre-registered systematic review of meta-analysis studies, randomized control trials, and observational studies evaluating clinical and biological features associated with heterogenous treatment effects for SGLT2-inhibitor and GLP1-receptor agonist therapies, considering glycaemic, cardiovascular, and renal outcomes. After screening 5,686 studies, we included 101 studies of SGLT2-inhibitors and 75 studies of GLP1-receptor agonists in the final systematic review.
Results: Here we show that the majority of included papers have methodological limitations precluding robust assessment of treatment effect heterogeneity. For SGLT2-inhibitors, multiple observational studies suggest lower renal function as a predictor of lesser glycaemic response, while markers of reduced insulin secretion predict lesser glycaemic response with GLP1-receptor agonists. For both therapies, multiple post-hoc analyses of randomized control trials (including trial meta-analysis) identify minimal clinically relevant treatment effect heterogeneity for cardiovascular and renal outcomes.
Conclusions: Current evidence on treatment effect heterogeneity for SGLT2-inhibitor and GLP1-receptor agonist therapies is limited, likely reflecting the methodological limitations of published studies. Robust and appropriately powered studies are required to understand type 2 diabetes treatment effect heterogeneity and evaluate the potential for precision medicine to inform future clinical care.
(© 2023. Springer Nature Limited.)
التعليقات: Update of: medRxiv. 2023 Apr 22:2023.04.21.23288868. doi: 10.1101/2023.04.21.23288868. (PMID: 37131814)
References: Diabetes Care. 2021 May;44(5):1236-1241. (PMID: 33707305)
Diabetes Res Clin Pract. 2022 Jan;183:109146. (PMID: 34780865)
Diabetes Obes Metab. 2021 Oct;23(10):2207-2214. (PMID: 33973690)
J Diabetes Investig. 2019 May;10(3):760-770. (PMID: 30412655)
Am Heart J. 2021 Sep;239:59-63. (PMID: 33905751)
Diabetes Ther. 2019 Aug;10(4):1453-1463. (PMID: 31240562)
Diabetes Obes Metab. 2022 Apr;24(4):662-674. (PMID: 34908223)
Diabetes Obes Metab. 2021 Sep;23(9):2077-2089. (PMID: 34047459)
Diabetes Metab Res Rev. 2017 Sep;33(6):. (PMID: 28303626)
Diabetes Obes Metab. 2020 Jul;22(7):1207-1214. (PMID: 32030863)
Lancet. 2019 Jan 5;393(10166):31-39. (PMID: 30424892)
Lancet. 2022 Nov 19;400(10365):1788-1801. (PMID: 36351458)
JACC Heart Fail. 2021 Aug;9(8):568-577. (PMID: 34325887)
Circulation. 2019 May 28;139(22):2516-2527. (PMID: 30882239)
PLoS One. 2019 Aug 1;14(8):e0220667. (PMID: 31369642)
J Clin Endocrinol Metab. 2021 Apr 23;106(5):1345-1351. (PMID: 33537745)
BMJ. 2009 Jul 21;339:b2700. (PMID: 19622552)
J Pers Med. 2022 Mar 09;12(3):. (PMID: 35330424)
Diabetes Metab Syndr Obes. 2020 Aug 05;13:2765-2779. (PMID: 32821142)
Diabet Med. 2017 Feb;34(2):197-203. (PMID: 27412701)
Int J Clin Pract. 2018 Mar;72(3):e13055. (PMID: 29341370)
Diabetes Obes Metab. 2021 Aug;23(8):1886-1891. (PMID: 33950573)
Pharmacogenomics. 2019 Mar;20(4):273-277. (PMID: 30883264)
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1705-1714. (PMID: 33214158)
Ann Intern Med. 2020 Jun 2;172(11):776. (PMID: 32479147)
Cardiovasc Diabetol. 2020 Sep 30;19(1):156. (PMID: 32998732)
Eur J Heart Fail. 2021 Jun;23(6):1012-1022. (PMID: 33599357)
Diabetes Obes Metab. 2020 Dec;22(12):2487-2492. (PMID: 32744418)
Diabetes Obes Metab. 2020 Sep;22 Suppl 4:35-47. (PMID: 33404200)
BMJ Open Diabetes Res Care. 2022 Apr;10(2):. (PMID: 35383100)
Diabetes Obes Metab. 2020 Feb;22(2):203-211. (PMID: 31595657)
Circulation. 2019 Apr 23;139(17):2022-2031. (PMID: 30786725)
Diabetes Metab Syndr. 2020 May - Jun;14(3):181-187. (PMID: 32142999)
Diabetes Obes Metab. 2016 Jul;18(7):725-8. (PMID: 26936426)
Pharmaceut Med. 2019 Jun;33(3):209-217. (PMID: 31933292)
Diabetes Metab Syndr Obes. 2019 Dec 27;12:2745-2753. (PMID: 31920354)
Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869. (PMID: 30292589)
Diabetes Obes Metab. 2021 Jul;23(7):1672-1676. (PMID: 33710721)
Diabetes Obes Metab. 2019 Aug;21(8):1925-1934. (PMID: 31050099)
Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. (PMID: 31495651)
Eur Heart J. 2020 Sep 14;41(35):3346-3358. (PMID: 32077924)
Cardiol Ther. 2017 Jun;6(1):129-132. (PMID: 27896705)
Circ J. 2017 Jan 25;81(2):227-234. (PMID: 28025462)
Diabetes Metab Syndr Obes. 2016 Oct 31;9:337-345. (PMID: 27822077)
N Engl J Med. 2020 Oct 8;383(15):1413-1424. (PMID: 32865377)
Diabetes Obes Metab. 2022 Jun;24(6):1114-1122. (PMID: 35233908)
Am J Nephrol. 2014;40(1):64-74. (PMID: 25059406)
Diabetes Obes Metab. 2016 Nov;18(11):1138-1142. (PMID: 27265893)
Diabetes Obes Metab. 2018 Jun;20(6):1520-1525. (PMID: 29573139)
Diabetes Obes Metab. 2018 Aug;20(8):2023-2028. (PMID: 29603872)
Ann Intern Med. 2019 Mar 19;170(6):423-426. (PMID: 30508430)
Diabetes Metab J. 2019 Apr;43(2):158-173. (PMID: 30688052)
Diabetes Obes Metab. 2017 Feb;19(2):275-283. (PMID: 27767249)
Lancet Diabetes Endocrinol. 2017 Sep;5(9):709-717. (PMID: 28781064)
J Am Coll Cardiol. 2022 Feb 8;79(5):432-444. (PMID: 35115099)
Diabetes Care. 2021 Aug;44(8):1805-1815. (PMID: 34233928)
Nat Med. 2023 Oct;29(10):2438-2457. (PMID: 37794253)
JAMA Cardiol. 2021 Feb 1;6(2):148-158. (PMID: 33031522)
Medicine (Baltimore). 2021 Nov 24;100(47):e27802. (PMID: 34964748)
Diabetologia. 2021 Jun;64(6):1226-1234. (PMID: 33611623)
Circulation. 2019 Nov 5;140(19):1569-1577. (PMID: 31474116)
BMJ. 2018 Dec 10;363:k4245. (PMID: 30530757)
Diabetologia. 2018 Aug;61(8):1712-1723. (PMID: 29777264)
Ann Intern Med. 2020 Aug 18;173(4):278-286. (PMID: 32598218)
Diabetes Obes Metab. 2020 Nov;22(11):2077-2088. (PMID: 32618386)
Value Health. 2017 Dec;20(10):1252-1259. (PMID: 29241884)
Diabetes Care. 2022 Nov 1;45(11):2753-2786. (PMID: 36148880)
Acta Diabetol. 2021 May;58(5):595-602. (PMID: 33452595)
Diabetol Metab Syndr. 2015 Nov 21;7:106. (PMID: 26594250)
Endocr Pract. 2011 May-Jun;17(3):345-55. (PMID: 21700561)
Diabetes Care. 2016 Feb;39(2):250-7. (PMID: 26242184)
Diabetes Ther. 2017 Dec;8(6):1349-1364. (PMID: 28983857)
Diabetes Obes Metab. 2020 Dec;22(12):2335-2347. (PMID: 32744354)
BMC Endocr Disord. 2014 Apr 18;14:37. (PMID: 24742013)
Circulation. 2018 Jul 31;138(5):458-468. (PMID: 29526832)
Diabetes. 2020 Oct;69(10):2075-2085. (PMID: 32843566)
J Clin Med. 2021 Mar 02;10(5):. (PMID: 33801192)
Clin Ther. 2016 Dec;38(12):2642-2651. (PMID: 27889301)
N Engl J Med. 2023 Jan 12;388(2):117-127. (PMID: 36331190)
PeerJ. 2020 Nov 17;8:e9998. (PMID: 33240585)
Circulation. 2018 Jan 9;137(2):119-129. (PMID: 28904068)
Ann Intern Med. 2021 Nov;174(11):1528-1541. (PMID: 34570599)
Diabetes Care. 2022 Feb 1;45(2):261-266. (PMID: 35050364)
Cardiovasc Diagn Ther. 2021 Jun;11(3):699-706. (PMID: 34295696)
PLoS One. 2022 Jan 12;17(1):e0261986. (PMID: 35020750)
J Clin Epidemiol. 2020 Mar;119:126-135. (PMID: 31711912)
Diabetes Metab Syndr Obes. 2013 Apr 08;6:123-9. (PMID: 23630427)
J Diabetes Investig. 2018 Jul;9(4):850-861. (PMID: 29029369)
Prim Care Diabetes. 2017 Oct;11(5):437-444. (PMID: 28583425)
J Am Coll Cardiol. 2020 Mar 17;75(10):1128-1141. (PMID: 32164886)
Diabetes Obes Metab. 2016 Aug;18(8):820-8. (PMID: 27161178)
Diabetes Obes Metab. 2020 Feb;22(2):263-266. (PMID: 31486272)
Circulation. 2018 Dec 18;138(25):2884-2894. (PMID: 30566004)
Circulation. 2020 Aug 25;142(8):734-747. (PMID: 32795086)
Curr Med Res Opin. 2020 Aug;36(8):1277-1284. (PMID: 32324082)
Cardiovasc Diabetol. 2019 Jun 6;18(1):73. (PMID: 31167654)
Diabetes Obes Metab. 2019 Jul;21(7):1745-1751. (PMID: 30851070)
Endocr Pract. 2011 Nov-Dec;17(6):906-13. (PMID: 22193143)
Eur Heart J. 2022 Aug 14;43(31):2958-2967. (PMID: 34427295)
Eur J Heart Fail. 2020 Jan;22(1):126-135. (PMID: 31820559)
J Card Fail. 2021 Aug;27(8):888-895. (PMID: 34364665)
J Clin Endocrinol Metab. 2020 Sep 1;105(9):. (PMID: 32485734)
Diabetes Obes Metab. 2017 Dec;19(12):1793-1797. (PMID: 28573708)
Diabetes Obes Metab. 2020 Sep;22(9):1690-1695. (PMID: 32372454)
Diabetes Care. 2021 Jan;44(1):210-216. (PMID: 33158949)
J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. (PMID: 31530577)
Diabetes Obes Metab. 2020 Dec;22(12):2276-2286. (PMID: 32700421)
J Am Heart Assoc. 2020 Jan 7;9(1):e012940. (PMID: 31902326)
Front Endocrinol (Lausanne). 2023 Jan 09;13:1091421. (PMID: 36699039)
Diabetes Care. 2020 Dec;43(12):3007-3015. (PMID: 33004464)
Diabetes Obes Metab. 2021 Feb;23(2):425-433. (PMID: 33084149)
Diabetes Obes Metab. 2016 Aug;18(8):829-33. (PMID: 27027802)
Diabetes Care. 2021 Nov;44(11):2542-2551. (PMID: 34593566)
Intern Med J. 2014 Apr;44(4):345-53. (PMID: 24877253)
Circulation. 2019 Nov 12;140(20):1613-1622. (PMID: 31542942)
Circulation. 2018 Dec 18;138(25):2908-2918. (PMID: 30566006)
JAMA Netw Open. 2022 Jan 4;5(1):e2142078. (PMID: 34985519)
JAMA Cardiol. 2021 Jul 1;6(7):801-810. (PMID: 33851953)
J Am Heart Assoc. 2018 Oct 2;7(19):e009304. (PMID: 30371301)
Diabetes Ther. 2020 Sep;11(9):2121-2143. (PMID: 32734559)
Cardiovasc Diabetol. 2020 Jun 13;19(1):83. (PMID: 32534570)
J Am Heart Assoc. 2021 Dec 7;10(23):e021661. (PMID: 34854308)
Endocrinol Diabetes Metab. 2018 Apr 06;1(2):e00016. (PMID: 30815552)
Eur J Heart Fail. 2021 Jun;23(6):1002-1008. (PMID: 33609071)
Diabet Med. 2018 Nov;35(11):1605-1612. (PMID: 29943854)
Diabetes Obes Metab. 2016 Jul;18(7):721-4. (PMID: 26679282)
JAMA Netw Open. 2022 Mar 01;5(3):e221169. (PMID: 35254430)
Acta Pharmacol Sin. 2015 Feb;36(2):200-8. (PMID: 25619391)
Nat Med. 2023 Feb;29(2):376-383. (PMID: 36477733)
Diabetologia. 2021 Oct;64(10):2147-2158. (PMID: 34415356)
Diabetes Obes Metab. 2018 Feb;20(2):409-418. (PMID: 28817231)
Kidney Int. 2018 Jan;93(1):231-244. (PMID: 28860019)
Diabetes Obes Metab. 2020 Mar;22(3):442-451. (PMID: 31903692)
Can J Diabetes. 2016 Jun;40(3):247-57. (PMID: 27052454)
Diabetes Technol Ther. 2017 Nov;19(11):685-691. (PMID: 28829163)
Pharmacol Res. 2020 Sep;159:104996. (PMID: 32574827)
Circulation. 2022 Feb 22;145(8):575-585. (PMID: 34903039)
Endocrinol Nutr. 2016 Apr;63(4):164-70. (PMID: 26830854)
Sci Rep. 2019 Sep 10;9(1):13009. (PMID: 31506585)
Am J Kidney Dis. 2021 Jan;77(1):23-34.e1. (PMID: 32971190)
Sci Rep. 2021 May 13;11(1):10166. (PMID: 33986377)
Kidney Med. 2021 Jun 19;3(5):732-744.e1. (PMID: 34746739)
Diabetes Obes Metab. 2019 Nov;21(11):2576-2580. (PMID: 31373167)
Clin J Am Soc Nephrol. 2021 Mar 8;16(3):384-395. (PMID: 33619120)
Diabetes Obes Metab. 2020 Dec;22(12):2384-2397. (PMID: 32744394)
J Diabetes Investig. 2022 Jun;13(6):975-985. (PMID: 35112504)
Circulation. 2019 Mar 12;139(11):1384-1395. (PMID: 30586757)
Pharmacogenomics. 2022 Apr;23(6):355-361. (PMID: 35311356)
Diabet Med. 2014 Apr;31(4):403-11. (PMID: 24246138)
Lancet Diabetes Endocrinol. 2023 Jan;11(1):33-41. (PMID: 36528349)
Diabetes Ther. 2020 May;11(5):1147-1159. (PMID: 32277401)
N Engl J Med. 2022 Sep 22;387(12):1089-1098. (PMID: 36027570)
Diabetes Ther. 2019 Jun;10(3):1113-1125. (PMID: 31055780)
Diabetes Obes Metab. 2020 Dec;22(12):2493-2498. (PMID: 32803900)
Endocr J. 2022 Jun 28;69(6):669-679. (PMID: 35314533)
Diabetes Care. 2018 Apr;41(4):705-712. (PMID: 29386249)
Diabetes Ther. 2017 Dec;8(6):1297-1308. (PMID: 29076038)
Curr Med Res Opin. 2015 Nov;31(11):1993-2000. (PMID: 26373629)
J Am Heart Assoc. 2022 Feb 15;11(4):e022376. (PMID: 35132865)
Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-662. (PMID: 34425083)
Cardiovasc Diabetol. 2020 Sep 29;19(1):154. (PMID: 32993654)
Acta Diabetol. 2018 Jun;55(6):557-568. (PMID: 29527621)
Adv Ther. 2014 Sep;31(9):986-99. (PMID: 25245811)
Circ Cardiovasc Interv. 2019 Dec;12(12):e008018. (PMID: 31752517)
Cardiovasc Diabetol. 2018 Jun 23;17(1):91. (PMID: 29935543)
J Clin Pharm Ther. 2020 Oct;45(5):1050-1057. (PMID: 32176827)
Diabetes Res Clin Pract. 2018 Sep;143:34-42. (PMID: 29935211)
N Engl J Med. 2021 Sep 2;385(10):896-907. (PMID: 34215025)
Diabet Med. 2016 Dec;33(12):1744-1747. (PMID: 26600115)
Clin Ther. 2020 Sep;42(9):1738-1749.e1. (PMID: 32753164)
Diabetologia. 2018 Jul;61(7):1522-1527. (PMID: 29713728)
Diabetes Obes Metab. 2018 Sep;20(9):2238-2245. (PMID: 29748996)
Diabetes Obes Metab. 2016 Jul;18(7):707-10. (PMID: 26662611)
Diabetes Obes Metab. 2021 Feb;23(2):455-466. (PMID: 33118320)
Diabetes Care. 2022 Apr 1;45(4):965-974. (PMID: 35120199)
J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583)
J Clin Endocrinol Metab. 2020 Feb 1;105(2):. (PMID: 31769496)
Clin Ther. 2015 Mar 1;37(3):574-84. (PMID: 25626486)
Diabetes Obes Metab. 2020 Jul;22(7):1141-1150. (PMID: 32227432)
Eur Heart J. 2016 May 14;37(19):1526-34. (PMID: 26819227)
معلومات مُعتمدة: P30 DK048520 United States DK NIDDK NIH HHS; MR/N00633X/1 United Kingdom MRC_ Medical Research Council; P30 DK116073 United States DK NIDDK NIH HHS; MR/T032014/1 United Kingdom MRC_ Medical Research Council; IK2 CX001907 United States CX CSRD VA; MR/K005707/1 United Kingdom MRC_ Medical Research Council; KL2 TR002490 United States TR NCATS NIH HHS; MR/W003988/1 United Kingdom MRC_ Medical Research Council; K01 HL157658 United States HL NHLBI NIH HHS
فهرسة مساهمة: Investigator: DK Tobias; J Merino; A Ahmad; C Aiken; JL Benham; D Bodhini; AL Clark; K Colclough; R Corcoy; SJ Cromer; D Duan; JL Felton; EC Francis; P Gillard; V Gingras; R Gaillard; E Haider; A Hughes; JM Ikle; LM Jacobsen; JLT Kettunen; RJ Kreienkamp; LL Lim; JME Männistö; R Massey; NM Mclennan; RG Miller; ML Morieri; J Most; RN Naylor; B Ozkan; KA Patel; SJ Pilla; K Prystupa; S Raghaven; MR Rooney; M Schön; Z Semnani-Azad; M Sevilla-Gonzalez; P Svalastoga; WW Takele; CH Tam; ACB Thuesen; M Tosur; AS Wallace; CC Wang; JJ Wong; JM Yamamoto; K Young; C Amouyal; MK Andersen; MP Bonham; M Chen; F Cheng; T Chikowore; SC Chivers; C Clemmensen; D Dabelea; AY Dawed; AJ Deutsch; LT Dickens; LA DiMeglio; M Dudenhöffer-Pfeifer; C Evans-Molina; MM Fernández-Balsells; H Fitipaldi; SL Fitzpatrick; SE Gitelman; MO Goodarzi; JA Grieger; M Guasch-Ferré; N Habibi; T Hansen; C Huang; A Harris-Kawano; HM Ismail; B Hoag; RK Johnson; AG Jones; RW Koivula; A Leong; GKW Leung; IM Libman; K Liu; SA Long; WL Lowe; RW Morton; AA Motala; S Onengut-Gumuscu; JS Pankow; M Pathirana; S Pazmino; D Perez; JR Petrie; CE Powe; A Quinteros; R Jain; D Ray; M Ried-Larsen; Z Saeed; V Santhakumar; S Kanbour; S Sarkar; GSF Monaco; DM Scholtens; E Selvin; WH Sheu; C Speake; MA Stanislawski; N Steenackers; AK Steck; N Stefan; J Støy; R Taylor; SC Tye; GG Ukke; M Urazbayeva; B Van der Schueren; C Vatier; JM Wentworth; W Hannah; SL White; G Yu; Y Zhang; SJ Zhou; J Beltrand; M Polak; I Aukrust; E de Franco; SE Flanagan; KA Maloney; A McGovern; J Molnes; M Nakabuye; PR Njølstad; H Pomares-Millan; M Provenzano; C Saint-Martin; C Zhang; Y Zhu; S Auh; R de Souza; AJ Fawcett; C Gruber; EG Mekonnen; E Mixter; D Sherifali; RH Eckel; JJ Nolan; LH Philipson; RJ Brown; LK Billings; K Boyle; T Costacou; JM Dennis; JC Florez; AL Gloyn; MF Gomez; PA Gottlieb; SAW Greeley; K Griffin; AT Hattersley; IB Hirsch; MF Hivert; KK Hood; JL Josefson; SH Kwak; LM Laffel; SS Lim; RJF Loos; RCW Ma; C Mathieu; N Mathioudakis; JB Meigs; S Misra; V Mohan; R Murphy; R Oram; KR Owen; SE Ozanne; ER Pearson; W Perng; TI Pollin; R Pop-Busui; RE Pratley; LM Redman; MJ Redondo; RM Reynolds; RK Semple; JL Sherr; EK Sims; A Sweeting; T Tuomi; MS Udler; KK Vesco; T Vilsbøll; R Wagner; SS Rich; PW Franks
Local Abstract: [plain-language-summary] This study reviews the available evidence on which patient features (such as age, sex, and blood test results) are associated with different outcomes for two recently introduced type 2 diabetes medications: SGLT2-inhibitors and GLP1-receptor agonists. Understanding what individual characteristics are associated with different response patterns may help clinical providers and people living with diabetes make more informed decisions about which type 2 diabetes treatments will work best for an individual. We focus on three outcomes: blood glucose levels (raised blood glucose is the primary symptom of diabetes and a primary aim of diabetes treatment is to lower this), heart disease, and kidney disease. We identified some potential factors that reduce effects on blood glucose levels, including poorer kidney function for SGLT2-inhibitors and lower production of the glucose-lowering hormone insulin for GLP1-receptor agonists. We did not identify clear factors that alter heart and kidney disease outcomes for either medication. Most of the studies had limitations, meaning more research is needed to fully understand the factors that influence treatment outcomes in type 2 diabetes.
تواريخ الأحداث: Date Created: 20231004 Latest Revision: 20240628
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10551026
DOI: 10.1038/s43856-023-00359-w
PMID: 37794166
قاعدة البيانات: MEDLINE
الوصف
تدمد:2730-664X
DOI:10.1038/s43856-023-00359-w